Results 81 to 90 of about 4,465 (91)
Some of the next articles are maybe not open access.

Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology
LBA3510 Background: In CodeBreaK 300 (NCT05198934), soto+pani was superior to investigator’s choice at the primary analysis of progression-free survival (PFS) in patients (pts) with chemorefractory KRAS G12C-mutated mCRC (Fakih et al. NEJM. 2023).
M. Fakih   +17 more
semanticscholar   +1 more source

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.

New England Journal of Medicine, 2023
M. G. Fakih   +18 more
semanticscholar   +1 more source

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

The Lancet Oncology, 2020
A. Marabelle   +20 more
semanticscholar   +1 more source

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Nature, 2019
J. Canon   +36 more
semanticscholar   +1 more source

Forecasting geothermal temperature in western Yemen with Bayesian-optimized machine learning regression models

Geothermal Energy
A. Al-Fakih   +4 more
semanticscholar   +1 more source

LC-MS/MS-Guided Profiling and Network Pharmacology Analysis of Bioactive Compounds from Costus speciosus Targeting Type 2 Diabetes: Insights from Molecular Docking and Dynamics

Intelligent Pharmacy
T. M. Fakih   +6 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy